Works matching AU Hu, Yue‐Mei

Results: 16
    1
    2

    Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 14, p. 6195, doi. 10.1002/cam4.2399
    By:
    • Zhu, Feng‐Cai;
    • Hu, Shang‐Ying;
    • Hong, Ying;
    • Hu, Yue‐Mei;
    • Zhang, Xun;
    • Zhang, Yi‐Ju;
    • Pan, Qin‐Jing;
    • Zhang, Wen‐Hua;
    • Zhao, Fang‐Hui;
    • Zhang, Cheng‐Fu;
    • Yang, Xiaoping;
    • Yu, Jia‐Xi;
    • Zhu, Jiahong;
    • Zhu, Yejiang;
    • Chen, Feng;
    • Zhang, Qian;
    • Wang, Hong;
    • Wang, Changrong;
    • Bi, Jun;
    • Xue, Shiyin
    Publication type:
    Article
    3

    Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.

    Published in:
    Cancer Medicine, 2017, v. 6, n. 1, p. 12, doi. 10.1002/cam4.869
    By:
    • Zhu, Feng‐cai;
    • Hu, Shang‐Ying;
    • Hong, Ying;
    • Hu, Yue‐Mei;
    • Zhang, Xun;
    • Zhang, Yi‐Ju;
    • Pan, Qin‐Jing;
    • Zhang, Wen‐Hua;
    • Zhao, Fang‐Hui;
    • Zhang, Cheng‐Fu;
    • Yang, Xiaoping;
    • Yu, Jia‐Xi;
    • Zhu, Jiahong;
    • Zhu, Yejiang;
    • Chen, Feng;
    • Zhang, Qian;
    • Wang, Hong;
    • Wang, Changrong;
    • Bi, Jun;
    • Xue, Shiyin
    Publication type:
    Article
    4
    5
    6
    7
    8

    Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.

    Published in:
    Expert Review of Vaccines, 2017, v. 16, n. 11, p. 1155, doi. 10.1080/14760584.2017.1374181
    By:
    • Wang, Shi-Yuan;
    • Liu, Shu-Zhen;
    • Chu, Kai;
    • Zhao, Yue;
    • Zhu, Feng-Cai;
    • Hu, Yue-Mei;
    • Meng, Fan-Yue;
    • Li, Jing-Xin;
    • Luo, Li;
    • Yang, Jia-Ying;
    • Liu, Pei;
    • Yu, Jun
    Publication type:
    Article
    9
    10

    Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women.

    Published in:
    SCIENCE CHINA Life Sciences, 2020, v. 63, n. 4, p. 582, doi. 10.1007/s11427-019-9547-7
    By:
    • Hu, Yue-Mei;
    • Guo, Meng;
    • Li, Chang-Gui;
    • Chu, Kai;
    • He, Wen-Gang;
    • Zhang, Jing;
    • Gu, Jian-Xiang;
    • Li, Juan;
    • Zhao, Hui;
    • Wu, Xiang-Hong;
    • Lin, BiZhen;
    • Lin, Zhi-Jie;
    • Yao, Xing-Mei;
    • Li, Ya-Fei;
    • Wei, FeiXue;
    • Huang, Yue;
    • Su, Ying-Ying;
    • Zhu, Feng-Cai;
    • Huang, Shou-Jie;
    • Pan, Hui-Rong
    Publication type:
    Article
    11

    Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomized controlled trial.

    Published in:
    International Journal of Cancer, 2014, v. 135, n. 11, p. 2612, doi. 10.1002/ijc.28897
    By:
    • Zhu, Feng‐Cai;
    • Chen, Wen;
    • Hu, Yue‐Mei;
    • Hong, Ying;
    • Li, Juan;
    • Zhang, Xun;
    • Zhang, Yi‐Ju;
    • Pan, Qin‐Jing;
    • Zhao, Fang‐Hui;
    • Yu, Jia‐Xi;
    • Zhang, Yan‐Shu;
    • Yang, Xiaoping;
    • Zhang, Cheng‐Fu;
    • Tang, Haiwen;
    • Zhang, Helen;
    • Lebacq, Marie;
    • David, Marie‐Pierre;
    • Datta, Sanjoy K;
    • Struyf, Frank;
    • Bi, Dan
    Publication type:
    Article
    12
    13
    14
    15
    16